Artwork
iconShare
 

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on July 14, 2025 18:40 (3d ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Manage episode 492462287 series 3675500
Content provided by International Parkinson and Movement Disorder Society, International Parkinson, and Movement Disorder Society. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by International Parkinson and Movement Disorder Society, International Parkinson, and Movement Disorder Society or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this episode, Dr. Michele Matarazzo interviews Prof. Tom Foltynie about the recently published phase 3 clinical trial of exenatide as a disease-modifying therapy for Parkinson’s disease in The Lancet. While the findings were disappointing, ongoing post-hoc analyses aim to understand the discrepancy with previous phase 2 results and explore how they might shape the future of exenatide and other GLP-1 agonists in neurodegenerative disorders. Read the article.
  continue reading

239 episodes